Do Drug Price Caps Improve Adherence to Treatment? RWE Indicates They Can

The Inflation Reduction Act (IRA) is often described as a pricing policy. In practice, it is a market disruptor.

By capping out-of-pocket insulin costs for Medicare beneficiaries, the IRA is changing how patients engage with treatment, how outcomes unfold over time, and how life sciences organizations are expected to demonstrate value.

Pricing reform is no longer limited to reimbursement mechanics. It is actively reshaping real-world access and value-based outcomes performance.

For life sciences teams, the insulin cost cap signals a broader shift. Evidence strategies must now account for how policy directly influences patient behavior and outcomes.

When cost changes, behavior changes

Lower costs don’t just improve access – they influence how likely it is that patients will stick to their prescribed treatments.

As the insulin cost cap reduces out-of-pocket cost burden, patients are less likely to delay treatment, ration medication, or discontinue therapy altogether. These behavioral shifts have a direct impact on health outcomes, health resource utilization, and the long-term cost of care.

Understanding and measuring these changes is critical for navigating market access, pricing, and policy strategy.

What the data reveals about the insulin cost cap

Research conducted by Inovalon and the Pharmacy Quality Alliance provides early insight into how the insulin cost cap is influencing patient behavior.

Using nationally representative claims-based data, the analysis examined basal insulin persistence among Medicare Advantage beneficiaries across two consecutive years. One year reflected behavior before the insulin cost cap. The following year captured outcomes after implementation.

The findings showed a statistically significant increase in treatment persistence after the insulin cost cap took effect. When patients remain on therapy longer, it can reduce avoidable complications, improve health status, influence health services utilization patterns, and impact total cost of care. These are the outcomes payers and policymakers look to when evaluating whether pricing reforms like the insulin cost cap are delivering meaningful results.

The analysis also revealed important variation across populations. Larger gains in persistence were observed among younger beneficiaries, male patients, individuals identified as Black, and those living in regions with a high prevalence of Type 2 diabetes (i.e., the “Diabetes Belt”).

Together, these findings show that the insulin cost cap is already reshaping patient behavior and that its impact is not uniform across populations. The research also points to opportunities for more targeted patient support programs, benefit design decisions, and future policy and research initiatives.

Pricing reform is redefining value

The IRA is raising expectations for how value is demonstrated.

Payers and regulators increasingly want proof that pricing decisions translate into meaningful real-world benefit across populations. That means showing how reforms affect adherence, persistence, and outcomes in practice, not just in theory.

Organizations that can quantify these effects with credible real-world evidence (RWE) are better positioned to support coverage discussions, strengthen value narratives, and engage confidently in policy dialogue. Those that rely primarily on list price or static assumptions risk falling behind as evidence standards continue to rise.

Future-proofing market access with RWE

As drug pricing and reimbursement policies continue to evolve, life sciences teams, health plans, and manufacturers need evidence strategies that can evolve just as quickly. To stay ahead, organizations must be able to:

• Measure patient behavior before and after policy changes
• Link affordability shifts to outcomes and utilization
• Support payer, regulatory, and policy engagement with defensible data

RWE is no longer optional. It is essential for navigating pricing reform and sustaining competitive advantage.

Stay ahead of IRA-driven change

The IRA is doing more than cutting costs. Through policies like the insulin cost cap, it is reshaping patient behavior, market expectations, and how value is defined.

Watch our session and learn how RWE helps teams adapt to the real-world ripple effects of pricing reform with confidence.

Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.